Innate: Corporate Presentation (Innate Pharma) - May 8, 2015 - “Elderly AML patients in complete remission after induction and consolidation treatment – maintenance setting”; “Phase I dose-escalation including 23 patients in first CR, and extension including 12 patients”; “Doses ranged from 0.0003 to 3 mg/kg – Full KIR saturation at doses ≥1mg/kg”; “Good tolerance with mild and transient adverse events. MTD not reached. Clear PK/PD relationship”; “Clinical outcome (2 patients from extension excluded, one in CR2 and one for early relapse within 5-days”
P1 data • Acute Myelogenous Leukemia • Oncology
|